Skip to content

Study of Attentional Disorders in Patients Suffering From Idiopathic Generalized Epilepsy.

Study of Attentional Disorders in Patients Suffering From Idiopathic Generalized Epilepsy.

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05530109
Acronym
ATTENTIONEPIG
Enrollment
33
Registered
2022-09-07
Start date
2022-04-26
Completion date
2025-04-25
Last updated
2025-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Generalized Epilepsy

Keywords

Attention, Epilepsy, Connectivity, EEG

Brief summary

Attentional disorders have been reported in neuropsychological studies evaluating patients suffering from generalized idiopathic epilepsy, but the data are disparate (in terms of test protocol). We aim to describe attentional and executive function disorder in IGE thanks to the Epitrack scale, validated in this specific population. Our secondary objective is to study the dynamic of cortical activity during an attentional task (the ANT), in order to describe the alteration of cortical networks in epileptic patients presenting with attentional disturbance.

Interventions

OTHERNeuropsychological screening and high resolution EEG recording

Each participant will be assessed with a battery of neuropsychological tests including Epitrack, the Raven's progressive matrice, the MoCA, the D2-R test, the BDI-II test, the STAI and the Qolie-31. Then, a prolonged EEG recording at rest and during an attentional task (the ANT) will be realized

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Idiopathic generalized epilepsy followed-up during at least 2 years * At least one antiepileptic drug medication * No cognitive decline (MoCA score \>26) * Absence of concomitant pathology that could interfere with the purpose of the study. * Be affiliated to the social security system * Have signed an informed consent

Exclusion criteria

* Pregnancy * Not able to give consent (Article 1121-8 of the CSP) Vulnerable person Being deprived of liberty by judicial or administrative decision (Article L 1121-6 of the CSP) Have a high probability of not respecting the protocol or of abandoning the study

Design outcomes

Primary

MeasureTime frameDescription
Epitrack scale scoreAt 1 month after inclusionEPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. scale from 9-49 (9 worst score - 49 best score)

Secondary

MeasureTime frameDescription
Montreal Cognitive Assessment (MoCA) scoreAt 1 month after inclusionCognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26 .
D2-R test scoreAt 1 month after inclusioncortical source connectivity patterns.
BDI-II scoreAt 1 month after inclusionAnxiety-depressive symptoms score Beck Depressive Inventory Questionnaire (BDI-II) (score), higher scores mean worse outcome, value minimum of 0 maximum 63
Raven's progressive matrice scoresAt 1 month after inclusioncortical source connectivity patterns.
quality of life using the Qolie-31 self questionnaireAt 1 month after inclusionQuality Of Life In Epilepsy-Problems questionnaire (QOLIE31-P) questionnaire has been developed specifically to measure the quality of life of patients with epilepsy. The score ranges from 0 to 100 points. Higher scores reflect better quality of life; lower ones, worse quality of life.
High resolution Electro Encephalo Gram functional connectivity markers at rest and during the ANT taskAt 1 month after inclusionlimited number of reproducible resting activity patterns, brain networks involved in the absence of task performance
STAI scaleAt 1 month after inclusionAnxiety-depressive symptoms score The State-Trait Anxiety Inventory (STAI) is a self-questionnaire, 20 questions, a score is calculated, ranging from 20 to 80, a high score indicating the presence of anxiety.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026